Detroit-based Barbara Ann Karmanos Cancer Institute has become the first independent cancer center in the U.S. to provide a one-time gene therapy for the treatment of hemophilia B in adults.
The first patient received the therapy — called Hemgenix — Oct. 28, according to a March 23 news release from the cancer institute.
The standard treatment for hemophilia B requires routine infusions of factor IX replacement therapy to help reduce bleeding risk. After gene therapy, patients need infusions only when undergoing a medical procedure or experiencing physical trauma.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
